English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/168625
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

AutorPaiva, Bruno; Cedena, Maria-Teresa; Puig, Noemi; Arana, Paula; Vidriales, Maria Belén; Cordon, Lourdes; Flores-Montero, Juan; Gutiérrez, Norma Carmen; Martín-Ramos, María-Luisa; Martínez-López, Joaquín; Ocio, Enrique M. ; Hernandez, Miguel T.; Teruel, Ana-Isabel; Rosiñol, Laura; Echeveste, María-Asunción; Martínez, Rafael; Gironella, Mercedes; Oriol, Albert; Cabrera, Carmen; Martín, Jesús; Bargay, Joan; Encinas, Cristina; Gonzalez, Yolanda; Dongen, J. J. M. van; Orfao, Alberto ; Bladé, Joan; Mateos, Maria Victoria; Lahuerta, Juan José; San Miguel, Jesús F.
Fecha de publicación2016
EditorAmerican Society of Hematology
CitaciónBlood 127(25): 3165-3174 (2016)
ResumenThe value of minimal residual disease (MRD) in multiple myeloma (MM) has been more frequently investigated in transplant-eligible patients than in elderly patients. Because an optimal balance between treatment efficacy and toxicity is of utmost importance in patients with elderly MM, sensitive MRD monitoring might be particularly valuable in this patient population. Here, we used second-generation 8-color multiparameter-flow cytometry (MFC) to monitor MRD in 162 transplant-ineligible MM patients enrolled in the PETHEMA/GEM2010MAS65 study. The transition from first- to second-generation MFC resulted in increased sensitivity and allowed us to identify 3 patient groups according to MRD levels: MRD negative (<10; n = 54, 34%), MRD positive (between <10 and ≥10; n = 20, 12%), and MRD positive (≥10; n = 88, 54%). MRD status was an independent prognostic factor for time to progression (TTP) (hazard ratio [HR], 2.7; P = .007) and overall survival (OS) (HR, 3.1; P = .04), with significant benefit for MRD-negative patients (median TTP not reached, 70% OS at 3 years), and similar poorer outcomes for cases with MRD levels between <10 and ≥10 vs ≥10 (both with a median TTP of 15 months; 63% and 55% OS at 3 years, respectively). Furthermore, MRD negativity significantly improved TTP of patients >75 years (HR, 4.8; P < .001), as well as those with high-risk cytogenetics (HR, 12.6; P = .01). Using second-generation MFC, immune profiling concomitant to MRD monitoring also contributed to identify patients with poor, intermediate, and favorable outcomes (25%, 61%, and 100% OS at 3 years, respectively; P = .01), the later patients being characterized by an increased compartment of mature B cells. Our results show that similarly to transplant candidates, MRD monitoring is one of the most relevant prognostic factors in elderly MM patients, irrespectively of age or cytogenetic risk.
URIhttp://hdl.handle.net/10261/168625
Identificadoresdoi: 10.1182/blood-2016-03-705319
e-issn: 1528-0020
issn: 0006-4971
Aparece en las colecciones: (IBMCC) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.